CCND1 and pancreatic neoplasm: PG545 dramatically decreased the levels of β-catenin, phosphorylation of GSK3α/β and its downstream target, Cyclin D1 in all tested pancreatic cancer cells (AsPC-1, MiaPaCa-2, and Capan-1) in a concentration-dependent manner (Fig. 1A and S1A).